Please ensure Javascript is enabled for purposes of website accessibility

Why Co-Diagnostics Stock Is Jumping Today

By Keith Speights – May 4, 2020 at 12:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced two new markets for its COVID-19 diagnostics tests.

What happened

Shares of Co-Diagnostics (CODX 2.40%) were up 11.4% as of 12:17 p.m. EDT on Monday after rising as much as 15.8% earlier in the day. The strong gains came after the molecular diagnostics company announced that its Logix Smart COVID-19 test has been approved for sale in Mexico, and that the Saragene COVID-19 test made by its joint venture, CoSara, had been cleared for sale in India. Co-Diagnostics CEO Dwight Egan also stated that orders for the Logix Smart COVID-19 test "continue to be strong." 

So what

Gaining access to new markets is good news for any company, and these are particularly important ones for Co-Diagnostics. India is the second-most populous country in the world, while Mexico, with approximately 129 million people, is tenth.

Gloved hand holding a blood vial with a label showing a check mark in a box indicating positive for coronavirus

Image source: Getty Images.

It's not clear at this point how much Co-Diagnostics' sales will rise as a result of gaining access to these two markets. Several other companies also make COVID-19 tests.

Co-Diagnostics' joint venture could give it an advantage in India, however. CoSara operates a manufacturing facility in Ranoli, India, that has achieved Good Manufacturing Practice (GMP) certification. This facility has a large-scale production capacity that should help CoSara meet demand in the Indian market.

Now what

As of April 20, Co-Diagnostics had shipped its COVID-19 diagnostics tests to more than a dozen states and had received orders from nearly 50 countries. But volumes and sales matter more than geographic reach. It will likely be another couple of months before the company announces its first-quarter results. That's when investors will get more clarity about whether this healthcare company's meteoric share-price rise -- it's up more than 1,500% year to date -- is justified by its performance.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
CODX
$3.41 (2.40%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.